Manila Times Business
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
Data presentations across multiple kidney diseases illustrate the breadth of Biogen’s nephrology portfolio with EMPAVELI® (pegcetacoplan) and felzartamab, an investigational anti-CD38 monoclonal antibody. CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that fourteen abstracts highlighting data from its nephrology portfolio, including EMPAVELI® (pegcetacoplan) and investigational felzartamab, have been accepted for presentation at the 63rd European Renal A
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Bata, Django, De la Cruz lead coaching staff of new billiards NSA
2h ago
Tokenized Cash Management Advisory Group Publishes the Scope of Its Work Program
2h ago
COSMOBEAUTÉ MALAYSIA & BEAUTYEXPO 2026 RETURNS TO KLCC TO DRIVE B2B EXCELLENCE AND NEW BUSINESS FRONTIERS
2h ago
Regent Hong Kong Named Among First-Ever Winners of Condé Nast Traveler's Triple Crown Award
2h ago